Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Depreciation & Amortization (CF) (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed Depreciation & Amortization (CF) for 6 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 52.31% to $2.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.5 million through Dec 2025, down 41.22% year-over-year, with the annual reading at $11.5 million for FY2025, 41.22% down from the prior year.
  • Depreciation & Amortization (CF) hit $2.4 million in Q4 2025 for Lyell Immunopharma, down from $2.6 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $5.1 million in Q3 2023 to a low of $2.0 million in Q1 2021.
  • Historically, Depreciation & Amortization (CF) has averaged $4.2 million across 5 years, with a median of $4.6 million in 2021.
  • Biggest five-year swings in Depreciation & Amortization (CF): soared 270.56% in 2021 and later tumbled 52.31% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $4.6 million in 2021, then rose by 10.43% to $5.0 million in 2022, then increased by 0.32% to $5.1 million in 2023, then decreased by 0.61% to $5.0 million in 2024, then crashed by 52.31% to $2.4 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for LYEL at $2.4 million in Q4 2025, $2.6 million in Q3 2025, and $3.1 million in Q2 2025.